Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    TopAbstracts in Melanoma 11/19/2008 - (DGNews)
    TopAbstracts in Melanoma 10/22/2008 - (DGNews)
    Methyl Aminolevulinate Photodynamic Therapy an Alternative to Surgery for Superficial Basal-Cell Carcinoma: Presented at EADV - (DGDispatch)
    TopAbstracts in Melanoma 09/24/2008 - (DGNews)
    Chest X-ray Prior to Sentinel Lymph Node Biopsy May Not Be Useful in Initial Staging of Primary Melanoma: Presented at ESSO - (DGDispatch)

    News archive

     Recent webcasts/CME - Melanoma

    Webcasts/CME archive

     Recent cases - Melanoma
      A 90-Year-Old Woman with an Asymptomatic Spot on Her Cheek
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      Primary Malignant Melanoma of the Lower Oesophagus Presenting with Dysphagia and Upper Gastrointestinal Bleeding: A Case Report
      Cardiovascular Magnetic Resonance of the Charcoal Heart
      Ring Melanoma of the Ciliary Body: Clinical and Ultrasound Biomicroscopic Characteristics

      Cases archive
        




      my personal edition > melanoma > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Combination Therapy with Temozolomide and Thalidomide May Increase Survival in Advanced-Stage Metastatic Melanoma Patients

      A DGReview of :"Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma"
      Journal of Clinical Oncology (JCO)

      09/24/2003
      By Jill Taylor


      The combination of temozolomide and thalidomide administered orally on a low-dose daily schedule has significant clinical activity in patients with advanced-stage metastatic melanoma, say researchers.

      Advanced-stage metastatic melanoma is associated with a poor prognosis, with no improvement in overall survival associated with current treatment options. Two orally bioavailable agents, temozolomide and thalidomide, offer favourable side effect profiles and anti-tumour activity that hypothetically may be enhanced when the drugs are combined.

      To investigate the efficacy and safety of such a treatment combination, Wen-Jen Hwu, MD, PhD, and colleagues of Memorial Sloan-Kettering Cancer Centre in New York, United States, performed an open label, phase II study of 38 patients with metastatic melanoma without brain metastases.

      Patients with histologically confirmed stage IV or IIIc metastatic melanoma were enrolled in the study. All patients received concomitant doses of temozolomide (75 mg/m2/day) and thalidomide (200 mg/day with dose escalation to 400 mg/day for patients < 70 years old or 100 mg/day with dose escalation to 250 mg/day for patients >/= 70 years old).

      Treatment was continued in 6-week cycles (after which temoxolomide treatment was interrupted for 2 weeks) until disease progression occurred or unacceptable toxicity levels were reached. The primary efficacy endpoint was complete (CR) or partial (PR) tumour response.

      Intent-to-treat analysis showed that 12 (32%) patients had an objective tumour response, including 11 patients with a PR and 1 patient with a CR continuing past 25 months. Of the patients achieving PR, 5 with a greater than 90% disease reduction were converted to a CR with surgery.

      Overall, 9 patients survived to a median follow up of 24.3 months. Median survival for responders was 24.1 months from time of first response, and median survival for non-responders 4.1 months.

      Brain metastases developed in 9 patients after a median follow up of 24.3 months, leading the researchers to hypothesize that the combination regimen might function to reduce central nervous system progression.

      Treatment was generally well tolerated. Lymphopaenia and leukopaenia were the primary haematologic adverse effects. Non-haematologic adverse effects included rash, constipation, vomiting, dizziness, dyspnoea, fatigue, nausea, headache, and infection, most of which were manageable. A total of 14 patients discontinued therapy due to adverse effects or other complications.

      "The combination of temozolomide plus thalidomide appears to be a promising and well-tolerated oral regimen for metastatic melanoma that merits further study," the investigators conclude.





      J Clin Oncol 2003 Sep 1;21:17:3351-6. "Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send